Glucocorticoids and vitamin D

Vitamin D

Volumn , Issue , 2011, Pages 1233-1244

  Sambrook, Philip ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884763904     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10066-6     Document Type: Chapter

References (90)

1. Weinstein R.S., Jilka R.L., Parfitt A.F., Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J. Clin. Invest. 1998, 102:272-282.
2. Plotkin L.I., Manolagas S.C., Bellido T. Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival: evidence for inside-out signaling leading to anoikis. J. Biol. Chem. 2007, 282:24120-24130.
3. Compston J. Management of glucocorticoid osteoporosis. Nat. Rev. Rheumatol. 2010, 6:82-88.
4. Canalis E., Mazziotti G., Giustina A., Bilzekian J.P. Glucocorticoid-induced osteoporosis, pathophysiology and therapy. Osteoporosis International 2007, 18:1319-1328.
5. Manolagas S.C. From estrogen to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocrine Reviews 2010, 31:3. 266-300.
6. Morris K.L., Zemel M.B. 1,25dihydroxyvitamin D3 modulation of adipocyte glucocorticoid function. Obes. Res. 2005, 13:670-677.
7. Sun X., Zemel M.B. 1a,25-Dihydroxyvitamin D and corticosteroid regulate adipocyte nuclear vitamin D receptor. International Journal of Obesity 2008, 32:1305-1311.
8. Bland R. Steroid hormone receptor expression and action in bone. Clin. Science 2000, 98:217-240.
9. Barnes P.J., Adcock I.M. Glucocorticoid resistance in inflammatory diseases. Lancet 2009, 373:1905-1917.
10. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable. Cell 1998, 15:487-490.
11. Chen T.L., Aronow L., Feldman D. Glucocorticoid receptors and inhibition of bone cell growth in primary culture. Endocrinology 1997, 100:619-628.
12. Chen T.L., Feldman D. Glucocorticoid receptors and actions in subpopulations of cultured rat bone cells. J. Clin. Invest. 1979, 63:750-757.
13. Haussler M.R., Manolagas S.C., Deftos L.J. Glucocorticoid receptor in clonal osteosarcoma cell lines: a novel system for investigating bone active hormones. Biochem. Biophys. Res. Commun. 1980, 94:373-380.
14. Masuyama A., Ouchi Y., Sato F., Hosoi T., Nakamura T., Orimo H. Characteristics of steroid hormone receptors in cultured MC3T3-E1 osteoblastic cells and effect of steroid hormones on cell proliferation. Calcif. Tissue Int. 1992, 51:376-381.
15. 3 receptors in cultured mouse osteosarcoma cells. Bone 1993, 14:7-12.
16. Liesegang P., Romalo G., Sudmann M., Wolf L., Schweikert H.U. Human osteoblast-like cells contain specific, saturable, high-affinity glucocorticoid, androgen, oestrogen, and 1alpha, 25-hydroxycholecalciferol receptors. J. Androl. 1994, 15:194-199.
17. Song L.N. Effects of retinoic acid and dexamethasone on proliferation, differentiation, and glucocorticoid receptor expression in cultured human osteosarcoma cells. Oncol. Res. 1994, 6:111-118.
18. Bland R., Worker C.A., Noble B.S., et al. Characterisation of 1 alpha -hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines. J. Endocrinol. 1999, 161:455-464.
19. Bellows C.G., Ciaccia A., Heersche J.N.M. Osteoprogenitor cells in cell populations derived from mouse and rat calvaria differ in the response to corticosterone, cortisol and cortisone. Bone 1998, 23:119-125.
20. Boden S.D., Hair G., Titus L., Racine M., McCuaig K., Wozney J.M., et al. Glucocorticoid induced differentiation of fetal rat calvarial osteoblasts is mediated by bone morphogenetic protein 6. Endocrinol. 1997, 138:2820-2828.
21. Ishida Y., Heersche J.M. Progesterone stimulates proliferation and differentiation of osteoprogenitor cells in bone cell populations derived from adult female but not from adult male rats. Bone 1997, 20:17-25.
22. Green E., Todd B., Heath D. Mechanism of glucocorticoid regulation of alkaline phosphatase gene expression in osteoblast-like cells. Eur. J. Biochem. 1990, 188:147-153.
23. Ogata T., Yamauchi M., Kim R.H., Li J.J., Freedman L.P., Sodek J. Glucocorticoid regulation of bone sialoprotein (BSP) gene-expression - identification of a glucocorticoid response element in the bone sialoprotein gene promoter. Eur. J. Biochem. 1995, 230:183-192.
24. Shalhoub V., Aslam F., Breen E., van Wijnen A., Bortell R., Stein G.S., et al. Multiple levels of steroid hormone-dependent control of osteocalcin during osteoblast differentiation: glucocorticoid regulation of basal and vitamin D stimulated gene expression. J. Cell Biochem. 1998, 69:154-168.
25. Conaway H.H., Grigorie D., Lerner U.H. Stimulation of neonatal mouse calvarial bone resorption by the glucocorticoids hydrocortisone and dexamethasone. J. Bone Miner. Res. 1996, 11:1419-1429.
26. 2. J. Bone Miner. Res. 1997, 12:734-741.
27. Wong M.M., Rao L.G., Ly H., Hamilton L., Tong J., Sturtridge W., et al. Long-term effects of physiologic concentrations of dexamethasone in human bone-derived cells. J. Bone Miner. Res. 1990, 5:803-813.
28. Subramaniam M., Colvard D., Keeting P.E., Rasmussen K., Riggs B.L., Spelsberg T.C. Glucocorticoid regulation of alkaline phosphatase, osteocalcin, and protooncogenes and normal human osteoblast-like cells. J. Cell Biochem. 1992, 50:411-424.
29. Sutherland M.S., Rao L.G., Muzaffar S.A., Wylie J.N., Wong M.M., McBroom R.J., et al. Age-dependent expression of osteoblastic phenotypic markers in normal human osteoblasts cultured long-term in the presence of dexamethasone. Osteop. Inter. 1995, 5:335-343.
30. Pockwinse S.M., Stein J.L., Lian J.B., Stein G.S. Developmental stage-specific cellular responses to vitamin D glucocorticoids during differentiation of the osteoblast phenotype: interelationship of morphology and gene expression by in situ hybridization. Exp. Cell Res. 1995, 216:244-260.
31. Patschan D., Loddenkemper K., Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 2001, 29:498-505.
32. 3. Proc. Natl. Acad. Sci. USA 1990, 87:369-373.
33. 3 and thyroid hormone in three osteosarcoma cell lines. Endocrinology 1995, 136:4304-4314.
34. 3 enhancement of mouse secreted phosphoprotein 1 (spp-1 or osteopontin) gene expression. Proc. Natl. Acad. Sci. USA 1990, 87:9995-9999.
35. 3 on growth, alkaline phosphatase and adenylate cyclase of rate osteoblast-like cells. Bone Miner. 1986, 1:397-405.
36. Owen T.A., Arnow M.S., Barone L.M., Bettencourt B., Stein.G.S., Lian J.B. Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phenotype: dependency upon basal levels of gene expression, duration of exposure, and bone matrix. Endocrinol. 1991, 128:1496-1504.
37. 3. J. Biol. Chem. 1982, 257:8009-8015.
38. Kream B.E., Rowe D., Smith M.D., Maher V., Majeska R. Hormonal regulation of collagen synthesis in a clonal rat osteosarcoma cell line. Endocrinol. 1986, 119:1922-1928.
39. 3inhibits transcription of type 1 collagen genes in the rat osteosarcoma cell line ROS 17/2.8. Endocrinol. 1989, 125:327-333.
40. Montecino M., Pockwinse S., Lian J., Stein G., Stein J. DNase I hypersensitive sites in promoter elements associated with basal and vitamin D dependent transcription of the bone-specific osteocalcin gene. Biochem. 1994, 33:348-353.
41. Morrison N.A., Shine J., Fragonas J.C., Verkest V., McMenemy M.L., Eisman J.A. 1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science 1989, 246:1158-1161.
42. Stromstedt P.E., Poellinger L., Gustafsson J.A., Carlstedt-Duke J. The glucocorticoid receptor binds to a sequence overlapping the TATA box of the human osteocalcin promoter: a potential mechanism for negative regulation. Mol. Cell Biol. 1991, 11:6. 3379-83.
43. Morrison N., Eisman J. Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter. J. Bone Min. Res. 1993, 8:969-975.
44. Aslam F., Shalhoub V., van Wijnen A.J., Banerjee C., Bortell R., Shakoori A.R., et al. Contributions of distal and proximal promoter elements to glucocorticoid regulation of osteocalcin gene transcription. Molecular Endocrinology 1995, 9:679-690.
45. Heinrichs A.A., Bortell R., Rahman S., Stein J.L., Alnemri E.S., Litwack G., et al. Identification of multiple glucocorticoid receptor binding sites in the rat osteocalcin gene promoter. Biochemistry 1993, 32:11436-11444.
46. Paredes R., Gutierrez J., Gutierrez S., Allison L., Puchi M., Imschenetzky M., et al. Interaction of the 1alpha,25-dihydroxyvitamin D3 receptor at the distal promoter region of the bone-specific osteocalcin gene requires nucleosomal remodelling. Biochemical J. 2002, 363:667-676.
47. Hidalgo A.A., Trump D.L., Johnson C.S. Glucocorticoid regulation of the vitamin D receptor. J. Steroid Biochem. Molec. Biol. 2010, 121. 372-275.
48. Kim M.H., Lee G.S., Jung E.M., Choi K.C., Jeung E.B. The negative effect of dexamethasone on calcium processing gene expressions is associated with a glucocorticoid induced calcium absorbing disorder. Lifesciences 2009, 85:146-152.
49. Dhawan P., Christakos S. Novel regulation of 25-hydroxyvitamin D(3) 24-hydroxylase (24(OH)ase) transcription by glucocorticoids: cooperative effects of the glucocorticoid receptor, C/EBPbeta, and the vitamin D receptor in 24(OH)ase transcription. J. Cellular Biochem. 2010, 110:1314-1323.
50. Banerjee A., Damera G., Bhandare R., Gu S., Lopez-Boado., Panettieri, Tliba O. Vitamin D and glucocorticoids differentially modulate chemokine expression in human airway smooth muscle cells. Brit. J. Pharmacol. 2008, 155:84-92.
51. Damera G., Fogle H.W., Lim P., Goncharova E.A., Zhao H., Banerjee A., et al. Vitamin D inhibits growth of human airway smooth muscle cells through growth factor-induced phosphorylation of retinoblastoma protein and checkpoint kinase 1. Brit. J. Pharmacol. 2009, 158:1426-1428.
52. Sutherland E.R., Goleva E., Jackson L.P., Stevens A.D., Leung D.Y.M. Vitamin D levels, lung function and steroid response in adult asthma. Am. J. Respir. Crit. Care Med. 2010, 181:699-704.
53. Xystrakis E., Kusumakar S., Boswell S., Peek E., Urry Z., Richards D.F., et al. Reversing the defective induction of IL-10 secreting regulatory T cells in glucocorticoid-resistant asthma patients. Journal of Clinical Investigation 2006, 116(1):146-155.
54. Akeno N., Matsunuma A., Maeda T., Kawane T., Horiuchi N. Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney. J. Endocrinol. 2000, 164:339-348.
55. Kurahashi l I., Matsunuma A., Kawane T., Abe M., Horiuchi N. Dexamethasone enhances vitamin D-24-hydroxylase expression in osteoblastic (UMR-106) and renal (LLC-PK1) cells treated with 1alpha,25-dihydroxyvitamin D3. Endocrine 2002, 17:109-118.
56. Chesney R.W., Hamstra A., Rose P., DeLuca H.F. Vitamin D and parathyroid hormone status in children with the nephrotic syndrome and chronic mild glomerulonephritis. Inter. J. Pediat. Neph. 1984, 5:1-4.
57. Chesney R.W., Mazess R.B., Hamstra A.J., DeLuca H.F., O'Reagan S. Reduction of serum-1, 25-dihydroxyvitamin-D3 in children receiving glucocorticoids. Lancet 1978, 2:1123-1125.
58. Morris H.A., Need A.G., O'Loughlin P.D., Horowitz M., Bridges A., Nordin B.E. Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif. Tiss. Int. 1990, 46:305-308.
59. Oettinger-Barak O., Segal E., Machtiei E.E., Barak S., Baruch Y., Ish-DShalom Alveolar bone loss in liver transplantation patients: relationship with prolonged steroid treatment and parathyroid hormone levels. J. Clin. Periodontol. 2007, 34:1039-1045.
60. Searing D.A., Zhang Y., Murphy J.R., Hauk P.J., Goleva E., Leung D.Y. Decreased serum vitamin D levels in children with asthma are associated with increased corticosteroid use. J. Allergy Clin. Immunol. 2010, 125:995-1000.
61. Toloza S.M., Cole D.E., Gladman D.D., Ibañez D., Urowitz M.B. Vitamin D insufficiency in a large female SLE cohort. Lupus 2010, 19:13-19.
62. Seeman E., Kumar R., Hunder G.G., Scott M., Heath H., Riggs B.L. Production, degradation, and circulating levels of 1,25-dihydroxyvitamin D in health and in chronic glucocorticoid excess. J. Clin. Invest. 1980, 66:664-669.
63. Slovik D.M., Neer R.M., Ohman J.L., Lowell F.C., Clark M.B., Segre G.V., et al. Parathyroid hormone and 25-hydroxyvitamin D levels in glucocorticoid-treated patients. Clin. Endocrinol. 1980, 12:243-248.
64. Hahn T.J., Halstead L.R., Baran D.T. Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J. Clin. Endoc. Metab. 1981, 1:111-115.
65. Hahn T.J., Halstead L.R., Teitelbaum S.L., Hahn B.H. Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. J. Clin. Invest. 1979, 64:655-665.
66. Findling J.W., Adams N.D., Lemann J., Gray R.W., Thomas C.J., Tyrrell J.B. Vitamin D metabolites and parathyroid hormone in Cushing's syndrome: relationship to calcium and phosphorus homeostasis. J. Clin. Endoc. Metab. 1982, 54:1039-1044.
67. Prummel M.F., Wiersinga W.M., Lips P., Sanders G.T.B., Sauerwein H.P. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J. Clin. Endocrinol. Metab. 1991, 72. 382-367.
68. Cosman F., Nieves J., Herbert J., Shen V., Lindsay R. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J. Bone Miner. Res. 1994, 9:1097-1105.
69. Klein R.G., Arnaud S.B., Gallagher J.C., De Luca H.F., Riggs B.L. Intestinal calcium absorption in exogenous hypercortisolism, Role of 25-hydroxyvitamin D and corticosteroid dose. J. Clin. Invest. 1977, 60:253-259.
70. Caniggia A., Nuti R., Lore F., Vattimo A. Pathophysiology of the adverse effects of glucoactive corticosteroids on calcium metabolism in man. J. Ster. Biochem. 1981, 15:153-161.
71. Colette C., Monnier L., Pares Herbute N., Blotman F., Mirouze J. Calcium absorption in corticoid treated subjects effects of a single oral dose of calcitriol. Hormone Metab. Res. 1987, 19:335-338.
72. Braun J.J., Birkenhager-Frenkel D.H., Rietveld A.H., Juttmann J.R., Visser T.J., Birkenhager J.C. Influence of 1 alpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double blind controlled study. Clin. Endocrinol. 1983, 19:265-273.
73. Hahn T.J., Hahn B.H. Osteopenia in subjects with rheumatic diseases, principles of diagnosis and therapy. Semin. Arthritis Rheum. 1976, 6:165-188.
74. Bijlsma J.W., Raymakers J.A., Mosch C., Hoekstra A., Derksen R.H., Baart, et al. Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia. Clin. Exp. Rheumatol. 1988, 6:113-119.
75. Adachi J.D., Bensen W.G., Bianchi F., Cividino A., Pillersdorf S., Sebaldt R.J., et al. Vitamin D and calcium in the prevention of corticosteroid-induced osteoporosis: a three year follow up study. J. Rheumatol. 1996, 23:995-1000.
76. Buckley L.M., Leib E.S., Cartularo K.S., Vacek P.M., Cooper S.M. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low dose corticosteroids in patients with rheumatoid arthritis. Ann. Intern. Med. 1996, 125:961-968.
77. Sambrook P.N., Birmingham J., Kelly P.J., Kempler S., Pocock N.A., Eisman J.A. Prevention of corticosteroid osteoporosis; a comparison of calcium, calcitriol and calcitonin. New Engl. J. Med. 1993, 328:1747-1752.
78. Reginster J.Y., Kuntz D., Verdickt W., Wouters M., Guillevin L., Menkes C.J., et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteop. Inter. 1999, 9:75-81.
79. Sambrook P.N., Henderson N.K., Keogh A., MacDonald P., Glanville A., Spratt P., et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J. Bone Miner. Res. 2000, 15:1818-1824.
80. Dykman T.R., Haralson K.M., Gluck O.S., Murphy W.A., Teitelbaum S.L., Hahn T.J., et al. Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum. 1984, 27:1336-1343.
81. Lambrinoudaki I., Chan D.T., Lau C.S., Wong R.W., Yeung S.S., Kung A.W. Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study. J. Rheumatol. 2000, 27:1759-1765.
82. Richy F., Ethgen O., Bruyere O., Reginster J.Y. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporosis International 2004, 15:301-310.
83. de Nijs R.N., Jacobs J.W., Algra A., Lems W.F., Bijlsma J.W. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporosis International 2004, 15:589-602.
84. Ringe J.D., Coster A., Meng T., Schacht E., Umbach R. Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif. Tiss. Int. 1999, 65:337-340.
85. Ringe J.D., Dorst A., Faber H., Schacht.E. Treatment of established glucocorticoid-induced osteoporosis with alfacalcidol or plain vitamin D. Calcif. Tiss. Int. 2003, 72:4.
86. Sambrook P.N., Kotowicz M., Nash P., Styles C.B., Naganathan V., Henderson-Briffa K.N., et al. Prevention and treatment of glucocorticoid induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium and alendronate plus calcium. J. Bone Miner. Res. 2003, 18:919-924.
87. de Nijs R.N.J., Jacobs J.W.G., Lems W.F., et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. New Engl. J. Med. 2006, 355:675-684.
88. Yamada S., Takagi H., Tsuchiya H., Nakajima T., Ochiai H., Ichimura A., et al. Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients. Yakugaku. Zasshi. - J. Pharma. Soc. Japan 2007, 127:1491-1496.
89. Fujii N., Hamani T., Mikami S., Nagasawa Y., Isaka Y., Moriyama T., et al. Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). Nephrol. Dial Transplant. 2007, 22:1601-1607.
90. Okada Y., Nawata M., Nakayamada S., Saito K., Tanaka Y. Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. Nat. Clin. Pract. Rheumatol. 2009, 5:74-75.